Table 1.
Baseline demographics and clinical characteristics
| Characteristic | With VTE | Without VTE | All patients |
|---|---|---|---|
| (n = 62) | (n = 62) | (N = 124) | |
| Age, median (range), years | 67 (41, 85) | 66 (43, 82) | 67 (41, 85) |
| Male, n (%) | 28 (45.2) | 27 (43.5) | 55 (44.4) |
| Race, n (%) | |||
| White | 48 (77.4) | 48 (77.4) | 96 (77.4) |
| Black | 3 (4.8) | 5 (8.1) | 8 (6.5) |
| Asian | 1 (1.6) | 2 (3.2) | 3 (2.4) |
| Other | 2 (3.2) | 1 (1.6) | 3 (2.4) |
| Not reported | 8 (12.9) | 6 (9.7) | 14 (11.3) |
| Ethnicity, n (%) | |||
| Hispanic/Latino | 4 (6.5) | 7 (11.3) | 11 (8.9) |
| Not Hispanic/Latino | 49 (79.0) | 49 (79.0) | 98 (79.0) |
| Not reported/unknown | 9 (14.5) | 6 (9.7) | 15 (12.1) |
| BMI, median (range), kg/m2 | 24.40 (15.1, 40.7) | 26.20 (17.7, 49.1) | 24.95 (15.1, 49.1) |
| Creatinine clearance, median (range), mL/min | 87.00 (38.4, 184.8) | 90.00 (37.2, 265.8) | 88.80 (37.2, 265.8) |
| Khorana risk score categories, n (%) | |||
| Cancer | |||
| 2 - Very high-risk cancer | 40 (64.5) | 35 (56.5) | 75 (60.5) |
| 1 - High-risk cancer | 21 (33.9) | 25 (40.3) | 46 (37.1) |
| 1 - BMI >35 kg/m2 | 6 (9.7) | 10 (16.1) | 16 (12.9) |
| 1 - Platelet count >350 000/µL | 23 (37.1) | 21 (33.9) | 44 (35.5) |
| 1 - Hemoglobin <10 g/dL | 5 (8.1) | 8 (12.9) | 13 (10.5) |
| 1 - Leukocyte count >11 000/µL | 13 (21.0) | 15 (24.2) | 28 (22.6) |
| Total Khorana risk score, n (%) | |||
| <2 | 0 | 0 | 0 |
| 2 | 42 (67.7) | 43 (69.4) | 85 (68.5) |
| 3 | 17 (27.4) | 13 (21.0) | 30 (24.2) |
| 4 | 2 (3.2) | 6 (9.7) | 8 (6.5) |
| ≥5 | 1 (1.6) | 0 | 1 (0.8) |
| ECOG PS score | |||
| 0 | 16 (25.8) | 22 (35.5) | 38 (30.6) |
| 1 | 39 (62.9) | 33 (53.2) | 72 (58.1) |
| 2 | 7 (11.3) | 7 (11.3) | 14 (11.3) |
BMI, body mass index; ECOG PS, Eastern Cooperative Oncology Group performance status.